NEW YORK--(BUSINESS WIRE)--Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in individuals with motor impairment, today announced the ...

NEW YORK--(BUSINESS WIRE)--Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ ...

“BCI is a platform to re-connect people with injury or disease back to the fast-moving consumer technology landscape,” said Synchron founder and CEO Tom Oxley, Ph.D. (Synchron) As brain-computer ...

BUFFALO, N.Y. – Results of the clinical trial that assessed the safety of Synchron’s endovascular brain-computer interface in people with severe paralysis will be presented Sept. 30 at the Congress of ...

Synchron, the brain-computer interface (BCI) company, has announced the world’s first-ever use of Apple Vision Pro, by one of the patients implanted with the Synchron brain computer interface. Mark, a ...

Apple's Vision Pro headset can now be controlled using only thoughts, thanks to integration with neurotechnology startup Synchron's brain-computer interface (BCI). The company today announced that ...

Apple has worked on a new standard with Synchron on a brain-computer interface that, among other things, aids folks with disabilities, according to the Wall Street Journal. Synchron has made a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Interim results from the COMMAND study evaluating the ...

A new protocol will allow users implanted with Synchron’s brain-computer interface (BCI) device to control iPhone, iPad and Apple Vision Pro directly with their thoughts without the need for physical ...

Neurotech company Synchron has been making massive strides over the past couple of years. It's just announced that a trial participant has used its brain-computer interface (BCI) to turn on the lights ...

In an industry-first, the company Synchron and Mount Sinai Hospital in New York have enrolled their first human patient in a U.S. clinical trial called COMMAND to evaluate an endovascular ...